MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

2015/09/26 by Matthew Fell, Matthew J. Fell, Christian Mirescu +20 · 8 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Parkinson's Disease Mechanisms and Treatments #Plant Gene Expression Analysis #Alzheimer's disease research and treatments

paper · doi:10.1124/jpet.115.227587

Cited by

• Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity
• Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
• Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
• Leucine-Rich Repeat Kinases
• Lysosome and Inflammatory Defects in GBA1‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition
• LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
• Parkinson's‐Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa
• Functionally active modulators targeting the LRRK2 WD40 repeat domain identified by FRASE-bot in CACHE Challenge #1